3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Leukemia, Myeloid, Acute
3
Leukemia, Lymphocytic, Chronic, B-Cell
2
Leukemia
2
Burkitt Lymphoma
2
Blast Crisis
2
Triple Negative Breast Neoplasms
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Ovarian Neoplasms
1
Oligodendroglioma
1
Neuroectodermal Tumors, Primitive
1
Myelodysplastic Syndromes
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large-Cell, Immunoblastic
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myelomonocytic, Acute
1
Leukemia, Myeloid
1
Gliosarcoma
1
Glioma, Subependymal
1
Glioma
1
Glioblastoma
1
Ependymoma
1
Congenital Abnormalities
1
Central Nervous System Neoplasms
1
Brain Neoplasms
1
Interventions
Cyclophosphamide
207
fludarabine phosphate
182
Azacitidine
153
fludarabine
141
Busulfan
139
Tacrolimus
118
Mycophenolic Acid
111
Cytarabine
110
Whole-Body Irradiation
105
Peripheral Blood Stem Cell Transplantation
97
Antilymphocyte Serum
95
Melphalan
89
Filgrastim
86
Cyclosporine
81
Methotrexate
78
Decitabine
78
venetoclax
63
Granulocyte Colony-Stimulating Factor
56
Radiotherapy
49
Stem Cell Transplantation
48
Thiotepa
46
Cord Blood Stem Cell Transplantation
43
thymoglobulin
41
Clofarabine
41
Etoposide
35
Specimen Handling
34
Methylprednisolone
34
Sirolimus
33
Biopsy
27
Injections
26
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Myelodysplastic Syndromes
×
Temozolomide
×
Other hematologic neoplasm
×
Clear all
NCT00687323
2017-06-07
TALL
Merck Sharp & Dohme LLC
Phase 2
Completed
47 enrolled
12 charts